115 related articles for article (PubMed ID: 27268659)
1. Targeted Bisulfite Sequencing-Based Analysis of MGMT Promoter Methylation in Meningiomas.
Bujko M; Kober P
Asian Pac J Cancer Prev; 2016; 17(5):2727-8. PubMed ID: 27268659
[No Abstract] [Full Text] [Related]
2. Pathodiagnostic parameters and evaluation of O⁶- methyl guanine methyl transferase gene promoter methylation in meningiomas.
Jabini R; Moradi A; Afsharnezhad S; Ayatollahi H; Behravan J; Raziee HR; Mosaffa F
Gene; 2014 Apr; 538(2):348-53. PubMed ID: 24398011
[TBL] [Abstract][Full Text] [Related]
3. Methylation of O6-methyl guanine methyltransferase gene promoter in meningiomas--comparison between tumor grades I, II, and III.
Larijani L; Madjd Z; Samadikuchaksaraei A; Younespour S; Zham H; Rakhshan A; Mohammadi F; Rahbari A; Moradi A
Asian Pac J Cancer Prev; 2014; 15(1):33-8. PubMed ID: 24528051
[TBL] [Abstract][Full Text] [Related]
4. Methylation status of MGMT gene promoter in meningiomas.
de Robles P; McIntyre J; Kalra S; Roldán G; Cairncross G; Forsyth P; Magliocco T; Hamilton M; Easaw J
Cancer Genet Cytogenet; 2008 Nov; 187(1):25-7. PubMed ID: 18992637
[TBL] [Abstract][Full Text] [Related]
5. Pyrosequencing Analysis of
Panagopoulos I; Gorunova L; Leske H; Niehusmann P; Johannessen LE; Staurseth J; Øino N; Meling TR; Heim S; Micci F; Brandal P
Cancer Genomics Proteomics; 2018; 15(5):379-385. PubMed ID: 30194078
[TBL] [Abstract][Full Text] [Related]
6. Identification of promoter region methylation patterns of MGMT, CDKN2A, GSTP1, and THBS1 genes in intracranial meningioma patients.
Aydemir F; Yurtcu E; Balci TB; Sahin FI; Gulsen S; Altinors N
Genet Test Mol Biomarkers; 2012 May; 16(5):335-40. PubMed ID: 22288845
[TBL] [Abstract][Full Text] [Related]
7. Meningeal hemangiopericytomas: a clinicopathological study with emphasis on MGMT (O(6) -methylguanine-DNA methyltransferase) promoter methylation status.
Kakkar A; Kumar A; Jha P; Goyal N; Mallick S; Sharma MC; Suri A; Singh M; Kale SS; Julka PK; Sarkar C; Suri V
Neuropathology; 2014 Aug; 34(4):333-42. PubMed ID: 24521400
[TBL] [Abstract][Full Text] [Related]
8. Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis.
Mikeska T; Bock C; El-Maarri O; Hübner A; Ehrentraut D; Schramm J; Felsberg J; Kahl P; Büttner R; Pietsch T; Waha A
J Mol Diagn; 2007 Jul; 9(3):368-81. PubMed ID: 17591937
[TBL] [Abstract][Full Text] [Related]
9. Applicability of HIN-1, MGMT and RASSF1A promoter methylation as biomarkers for detecting field cancerization in breast cancer.
Spitzwieser M; Holzweber E; Pfeiler G; Hacker S; Cichna-Markl M
Breast Cancer Res; 2015 Sep; 17(1):125. PubMed ID: 26370119
[TBL] [Abstract][Full Text] [Related]
10. [Prognostic implication of MGMT promoter methylation, activity and protein expression in cancer patients].
Chen Y; Qi H
Zhonghua Bing Li Xue Za Zhi; 2015 Jul; 44(7):539-42. PubMed ID: 26705056
[No Abstract] [Full Text] [Related]
11. Prognostic and predictive roles of MGMT protein expression and promoter methylation in sporadic pancreatic neuroendocrine neoplasms.
Schmitt AM; Pavel M; Rudolph T; Dawson H; Blank A; Komminoth P; Vassella E; Perren A
Neuroendocrinology; 2014; 100(1):35-44. PubMed ID: 25012122
[TBL] [Abstract][Full Text] [Related]
12. Status of O⁶ -methylguanine-DNA methyltransferase [MGMT] gene promoter methylation among patients with glioblastomas from India.
Nehru GA; Pai R; Samuel P; Chacko AG; Chacko G
Neurol India; 2012; 60(5):481-6. PubMed ID: 23135024
[TBL] [Abstract][Full Text] [Related]
13. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W;
Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102
[TBL] [Abstract][Full Text] [Related]
14. Relevance of MSP assay for the detection of MGMT promoter hypermethylation in glioblastomas.
Yachi K; Watanabe T; Ohta T; Fukushima T; Yoshino A; Ogino A; Katayama Y; Nagase H
Int J Oncol; 2008 Sep; 33(3):469-75. PubMed ID: 18695875
[TBL] [Abstract][Full Text] [Related]
15. Prognosis value of MGMT promoter methylation for patients with lung cancer: a meta-analysis.
Chen C; Hua H; Han C; Cheng Y; Cheng Y; Wang Z; Bao J
Int J Clin Exp Pathol; 2015; 8(9):11560-4. PubMed ID: 26617891
[TBL] [Abstract][Full Text] [Related]
16. Quantitative analysis of DNA methylation in the promoter region of the methylguanine-O(6) -DNA-methyltransferase gene by COBRA and subsequent native capillary gel electrophoresis.
Goedecke S; Mühlisch J; Hempel G; Frühwald MC; Wünsch B
Electrophoresis; 2015 Dec; 36(23):2939-50. PubMed ID: 26331436
[TBL] [Abstract][Full Text] [Related]
17. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
[TBL] [Abstract][Full Text] [Related]
18. Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter--still a dilemma?
Hegi ME; Stupp R
Neuro Oncol; 2015 Nov; 17(11):1425-7. PubMed ID: 26374690
[No Abstract] [Full Text] [Related]
19. Aberrant DNA methylation of alternative promoter of DLC1 isoform 1 in meningiomas.
Bujko M; Kober P; Rusetska N; Wakuła M; Goryca K; Grecka E; Matyja E; Neska J; Mandat T; Bonicki W; Siedlecki JA
J Neurooncol; 2016 Dec; 130(3):473-484. PubMed ID: 27614886
[TBL] [Abstract][Full Text] [Related]
20. The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer.
Gao D; Herman JG; Guo M
Oncotarget; 2016 Jun; 7(24):37331-37346. PubMed ID: 26967246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
